NCT05799248 is a Phase 3 clinical trial of rhPSMA-7.3 (18F) in Prostate Cancer, sponsored by MidLantic Urology.

Who is sponsoring NCT05799248?

NCT05799248 is sponsored by MidLantic Urology.

What drugs are being tested in NCT05799248?

Interventions in NCT05799248: rhPSMA-7.3 (18F).

What condition does NCT05799248 study?

NCT05799248 studies Prostate Cancer.

Is NCT05799248 still recruiting?

NCT05799248 is currently recruiting now. Last updated 24 May 2024.

Last reviewed 2024-05-24 · How we verify

NCT05799248

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

Recruiting now Phase 3 Last updated 24 May 2024

What this trial tests

Phase 3 trial testing rhPSMA-7.3 (18F) in Prostate Cancer in 113 participants. Currently enrolling.

Timeline

27 April 2023

Primary endpoint
28 May 2024

28 May 2024

Quick facts

Lead sponsor	MidLantic Urology
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	113
Start date	27 April 2023
Primary completion	28 May 2024
Estimated completion	28 May 2024
Sites	1 location across United States

Drugs / interventions tested

rhPSMA-7.3 (18F)

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

MidLantic Urology

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study Title: Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management Protocol number: BED-IIT-437 Phase: 3b Sponsor: MidLantic Urology Funding Organization: Blue Earth Diagnostics Ltd Study Design: This is a Phase 3b, multi-center, single-arm, diagnostic imaging study designed to detect metastatic lesions in men diagnosed with high-risk prostate cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05799248 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MidLantic Urology
Last refreshed: 24 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05799248.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing